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Background: Effective screening programs are urgently needed to provide undiagnosed hepatitis C virus
(HCV)-infected individuals with therapy. This systematic review of characteristics and outcomes of screening
programs for HCV focuses on strategies to identify HCV risk groups hidden in the general population.
Methods: We conducted a comprehensive search of MEDLINE and EMBASE databases for articles published
between 1991–2010, including studies that screened the general population using either a newly developed
(nonintegrated) screening program or one integrated in existing health care facilities. Look-back studies, prevalence
studies, and programs targeting high-risk groups in care (e.g., current drug users) were excluded.
Results: After reviewing 7052 studies, we identified 67 screening programs: 24 nonintegrated; 41 programs
integrated in a variety of health care facilities (e.g., general practitioner); and 2 programs with both integrated and
nonintegrated strategies. Together, these programs identified approximately 25,700 HCV-infected individuals. In
general, higher HCV prevalence was found in programs in countries with intermediate to high HCV prevalence, in
psychiatric clinics, and in programs that used a prescreening selection based on HCV risk factors. Only 6 programs
used a comparison group for evaluation purposes, and 1 program used theory about effective promotion for
screening. Comparison of the programs and their effectiveness was hampered by lack of reported data on program
characteristics, clinical follow-up, and type of diagnostic test.
Conclusions: A prescreening selection based on risk factors can increase the efficiency of screening in low-prevalence
populations, and we need programs with comparison groups to evaluate effectiveness. Also, program characteristics
such as type of diagnostic test, screening uptake, and clinical outcomes should be reported systematically.
Keywords: HCV, Testing, Case finding, Case detection, Reporting guidelinesBackground
Hepatitis C virus (HCV) infection, primarily a blood-borne
virus and first identified in 1989, is a major public health
problem. Worldwide an estimated 130–170 million individ-
uals are HCV-antibody positive [1], of whom approximately
75% are chronically infected and at risk for the development
of cirrhosis, which can lead to liver cancer and death [2,3].
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reproduction in any medium, provided the orand the development of cirrhosis are usually asymptomatic
[2,4]; many infections remain undetected or are diagnosed
at a late stage. In the United States of America (USA), an
estimated 43% to 72% of HCV infections are undiagnosed
[5-7]. In 2001, successful combination therapy for HCV be-
came widely accessible [8,9] and more effective therapeutic
options are becoming available [10,11]. Effective screening
programs are urgently needed to provide undiagnosed
HCV-infected individuals with therapy and to spread infor-
mation about preventive measures that each person should
take, thus decreasing future morbidity and mortality.
There are several types of screening strategies such as
mass population screening, selective screening, or casetd. This is an open access article distributed under the terms of the Creative
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screening of risk groups for HCV (see below) has been
recommended [13,14]. Some of the high risk groups for
HCV are relatively easy to reach and have been targeted
by screening programs as part of specialized medical
care (e.g., current drug users (DUs) on methadone treat-
ment who have injected drugs in the past [15], hemo-
philiacs [16], and HIV-infected individuals receiving
clinical care [17]). However, other risk groups are more
difficult to target for screening. For example, persons at
risk for HCV infection through occasional injecting drug
use (IDU) in the remote past will not attend programs
targeted at active injecting drug users and might not
identify themselves as being at risk for HCV infection.
The same holds true for individuals who received a
blood transfusion before 1992. These groups can be con-
sidered as ‘hidden risk groups’ among the general popu-
lation. The size of this hidden population may be
substantial. A recent study estimated that of the total
population of HCV-infected individuals in a high-
income country, only 34% are in relatively easy to reach
high-risk groups such as hemophiliac patients, HIV-
infected patients, and persons with a history of IDU;
41% are first-generation migrants and 25% belong to
other risk groups [18].
Risk groups for HCV infection [13,14]
 Individuals with a history of injecting drug use
(IDU), including those who injected only a limited
number of times many years ago and do not
consider themselves to be drug users
 Individuals who received clotting factor concentrates
produced before 1987 or a blood transfusion or an
organ transplant before 1992 including hemophiliac
patients (systematic screening of blood donors for
HCV antibodies was introduced in 1991) [19]
 Individuals with occupational exposure to infected
blood
 People living with HIV
 Chronic hemodialysis patients
 Children born to HCV-infected mothers
 Individuals exposed to HCV-infected blood through
invasive procedures or blood product transfusions
due to absence of precautionary measures to prevent
transmission, mostly in low-resource settings. This
group includes first-generation migrants.
Finding an effective strategy to identify the hidden
population of undiagnosed HCV-infected individuals is
challenging. An overview of HCV screening programs
provides insight into strategies that have been used so
far and their outcomes, and can provide insight into the
best way forward. In our review, we systematically evalu-
ate characteristics and outcomes of HCV screeningprograms targeted at risk groups hidden in the general
population. We focused in particular on the promotion
of the screening program, whether or not prescreening
selection criteria were used, and the use of psychosocial
theory or knowledge about determinants facilitating par-
ticipation in screening programs, since health promotion
programs that are based on theory are more likely to be
effective than those that are not [20]. We discuss the im-




We searched in the MEDLINE (PubMed) and EMBASE
databases for articles published in any language before
July 27, 2010. A comprehensive strategy was used to in-
clude all possible studies in which individuals were
screened for HCV. Search terms included hepatitis C
(Medical Subject Headings [MeSH] for PubMed and Ex-
plosion search [Exp] for Embase) or HCV or “hepatitis
C” in title or abstract combined with search terms in
title or abstract that reflect screening (i.e., mass screen-
ing [MeSH/Exp], screen*, “case finding*”, “case identifi-
cation*”, “case detection*”, “hepatitis C testing”, “HCV
testing”) or search terms in title or abstract and/or
MeSH/Exp that reflect campaigns or evaluation of health
programs (i.e., campaign*, health promotion, health ser-
vice*”, feasibility, pilot*, “program* evaluation*”, “pro-
gram* effect*”, “*health care quality”). The search was
limited to articles published after 1990 since a more sen-
sitive second-generation HCV antibody test was intro-
duced in 1991 [21]. The complete search strategy
including truncation characters is available from the au-
thors. In addition, we screened the reference lists of the
articles that were included in the selection.
Study selection
Studies were included if they reported screening of individ-
uals in the general population, including screening in pri-
mary care facilities that are not related to specific HCV
risk groups. Screening is defined as testing for HCV anti-
bodies. Exclusion criteria included ‘look-back’ studies, in
which recipients of HCV-infected donor blood are notified
and offered screening and studies conducted in specific,
identifiable risk groups for HCV that are in specialized
care: injecting drug users, HIV-infected individuals, incar-
cerated individuals, hemodialysis patients, or multitrans-
fused patients such as hemophiliac patients. In addition,
studies were excluded if 1) the study was designed to assess
the prevalence in a given population, and/or 2) if the study
was undertaken to investigate transmission rates and deter-
minants or the association between HCV infection and
another medical condition, and/or 3) nothing was reported
about notification, referral, or medical follow-up of
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studies, not aiming to identify HCV infections). The latter
criterion did not apply to studies describing HCV screening
at the general practitioner (GP) clinic, since notification of
results in this setting is considered to take place. Articles in
languages other than English, Dutch, French, German, or
Spanish were excluded if there was no English abstract of if
the English abstract did not yield enough data.
The first selection round was based on title and abstract
(if available) only and was done by four authors (FZ, AU,
CH, and CvdB). The database including the titles and ab-
stracts obtained through the search was split in four. The
reviewers independently screened two of the subdatabases
each so that each title/abstract was screened in duplicate.
Studies were included in the second screening round if se-
lected by at least one reviewer. The second selection
round comprised screening of the full-text articles. Two
authors (FZ and AU) independently screened all articles
for eligibility using the aforementioned criteria. Any dis-
crepancies were resolved by discussion until consensus
was reached, and unresolved discrepancies were arbitrated
by a third reviewer (MP).
Data extraction and validity checking
Data regarding program characteristics and program out-
comes (see Parameters of screening programs) were ex-
tracted and cross-checked by two reviewers (FZ and AU).
If the study reported HCV prevalence, but without speci-
fying whether it concerned HCV-antibody or HCV-
RNA prevalence, and if information about the test that
was used was lacking, we assumed it to be HCV-
antibody prevalence. Since the studies were performed
in different periods of time, different types of tests were
used over the years. Therefore the prevalences were
qualified depending on the test used. Anti-HCV and
HCV-RNA prevalence rates of studies were considered
suboptimal 1) if data was collected prior to 1994 when
sensitivity and specificity of tests were not optimal
[19,22] or 2) if studies did not confirm reactive HCV
antibody test results by immunoblot or PCR to eliminate
false positives. Tests were considered valid if performed
after 1993 and if 1) second- or higher- generation immu-
noblot assays from Ortho, Chiron, Novartis (RIBA), Inno-
genetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs
Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV
IgG 2.0) were used to confirm HCV antibody reactive re-
sults or 2) PCR was used to confirm HCV- antibody react-
ive results. The validity of outcomes of studies that did
not indicate which test was used, and studies that used
dried blood spot (DBS), oral fluid screening, or immuno-
blot assays different from those indicated above, was con-
sidered undecided.
We distinguished two types of settings and presented
the screening programs according to these: integratedand nonintegrated screening. Integrated screening refers
to programs that are integrated within already existing
health care facilities, whereas in nonintegrated screening,
the program is exclusively set up for the screening. In
addition, since screening strategies may differ according
to the HCV prevalence in a specific country, data are
presented not only by the type of setting, but also separ-
ately for low HCV prevalence (≤2%) ) and intermediate
to high HCV-prevalence countries (>2%; country-
specific prevalence estimates were obtained from refer-
ence [23]).
Parameters of screening programs
Program characteristics
 Country (and region, if applicable) of the study
 Estimated HCV antibody prevalence in the country
 Calendar year(s) of data collection
 Duration of enrolment/screening period
 Setting (i.e., whether HCV screening was
integrated within already existing health care
facilities or whether the program was exclusively
set up for the screening [i.e., nonintegrated
screening])
 Use of psychosocial theory or previous research
findings as a basis for communicating the
screening and for stimulating screening uptake
 Size of the targeted population
 Use of media activities and/or personal invitations
to promote screening
 Use of screening criteria based on HCV risk factors
 Incentive or participant’s costs for screening
 Anonymous or nonanonymous participation
 Type of HCV test(s) that was used for screening
 Screening for other diseases performed
 Use of a comparison group for evaluation purposes
Program outcomes
 Response rate (i.e., proportion of the target
population that was screened)
 Number of participants (i.e., number of individuals
that were screened)
 Number of HCV cases identified
 Number of HCV cases already known
 HCV-antibody prevalence
 Risk profile of identified cases
 Proportion of HCV-antibody positives with detect-
able HCV RNA
 Number of referrals to specialist
 Start and outcomes of treatment
Results
The search strategy identified 5,263 records from the
MEDLINE database and 6,300 from the EMBASE data-
base. After duplicates were eliminated, 7,052 of 11,563
records remained. Of those, 737 were selected as potentially
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and reviewed independently in duplicate. We excluded
677 articles; 652 articles because they did not meet the in-
clusion criteria (the majority because they were prevalence
studies, or studies that only reported statements about
HCV screening guidelines and policy, not including any
screening results), and 3 Japanese articles and 1 Italian be-
cause they did not provide an English abstract. In addition,
20 articles (two Chinese [24,25], eight Japanese [26-33],
one Icelandic [34], four Russian [35-38], two Turkish
[39,40], one Czech [41], and two Taiwanese [42,43])
seemed relevant on the basis of the English abstracts,
but were excluded as the abstracts alone did not yield
enough information for review. One article was excluded
because the same data were reported in two papers
[44,45]. Of the 60 studies remaining, references lists were
screened yielding an additional 106 potentially relevant
records. The full-text articles were retrieved and screened
independently in duplicate, and 7 of the 106 studies were
selected for inclusion. In total, 67 studies remained in the
final selection.
The 67 studies identified were done in the USA (n = 27),
Europe (n = 27; mostly France and the United Kingdom
[UK]), Asia (n = 4), Australia (n = 4), South America (n = 3),
Egypt (n = 1) and Saudi Arabia (n = 1). We identified 24
nonintegrated and 41 integrated studies, plus two studies
that used both strategies (the latter are shown in the
paragraph below for the results of the nonintegrated
part of their program, and in the subsequent para-
graphs for the results of the integrated part of their
program) [46,47]. A total of 85% (22/26) of the non-
integrated programs and all of the integrated programs
were from low HCV-prevalence countries.
Nonintegrated HCV screening programs in low HCV-
prevalence countries (n = 22)
Program characteristics
Additional file 1: Table S1 presents the 20 nonintegrated
HCV screening programs and the 2 programs that com-
bined an integrated and non-integrated screening ap-
proach that were performed in low HCV prevalence
countries. In total, 12 of the 22 programs were carried out
in the USA. The table is sorted by population type; seven
studies were aimed at screening the general population;
the other 15 studies targeted specific groups in which a
higher HCV prevalence might have been expected (e.g.,
migrants, homeless individuals, firefighters, surgeons).
Five of the 22 programs reported the use of personal
screening invitations either face to face or by mail, and
12 reported the use of media activities to attract individ-
uals for screening. Eight studies reported the possibil-
ity for individuals to participate anonymously. Only
nine of 22 studies reported the costs for participants to
be screened; in all of them, screening was offered freeof cost, and one study offered a t-shirt as an incentive for
screening [48].
With respect to screening procedures, except for two,
all programs used venipuncture to collect serum. A pro-
gram targeted at firefighters [49] used home specimen
collection kits for serum collection. A program targeted
at migrants [46] initially used oral fluid HCV antibody
tests followed by a blood test for those who tested posi-
tive (no further details reported). In the majority (16/22)
of the programs, participants were also screened for
other infections (mostly HIV and hepatitis B virus
[HBV]) or elevated liver enzymes (alanine aminotrans-
ferase [ALT], aspartate aminotransferase [AST]).
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 19 to 8,650. The screening
uptake was reported in 13/22 studies, and varied from
>20% in a screening program at a local health fair in
the USA [50] to 100% in a program that used house-
hold visits to identify transfusion recipients and invite
them for screening in Cuba [51]. The HCV prevalence
varied from 0% to 28.3%. The latter was found in a
community-based screening program in New York City
targeted at migrants from the former Sovjet Union. HCV
risk-profile data were available for only a subset of the
HCV-infected individuals in that study and included
intramuscular injections and blood transfusions. Some of
the programs among a so-called ‘general population’ (see
Additional file 1: Table S1, row 1–7) that found relatively
high HCV prevalences (e.g., 10.5% in a walk-in clinic
[52]), did not collect risk profile data of their participants,
limiting the interpretability of their findings. Two of 22
studies used a prescreening risk assessment in order to
limit screening to those with established HCV risk factors:
one did not report the prevalence nor screening uptake
[53]; the study in Cuba reported the highest screening
uptake (100%) and found relatively high HCV prevalence
(8.6%), but absolute numbers were small.
Four of the 22 programs screened primarily people
from Asia, either through screening programs in Asia
(Japan), or programs in Western countries targeting
Asian migrants. In all but one of these programs, relatively
high HCV prevalences were found, varying from 5.2% to
19.7%. In contrast, the programs targeting those with oc-
cupational risk for HCV (n = 7) found relatively low HCV
prevalences (all <1.1%, except for 3.6% among firefighters
and 5.3% among health care workers involved with liver
transplantations).
We did not notice clear differences in screening uptake
or HCV prevalence related to the use of personal invita-
tions for screening, the use of media to attract individuals
for screening, and whether or not individuals were
screened for other infections as well. In general, a lower
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provided anonymous screening for HCV; however, most
of these studies (6/8) targeted those with occupational risk
for HCV, explaining the lower prevalence.
Only one study compared the results of their outreach
screening program with data collected in the same
period at a screening clinic that is visited by individuals
on their own initiative [54]. A higher prevalence of HCV
was found during outreach screening (4.9% versus 1.6%,
respectively). However, the number of individuals that
returned to obtain their test results was much lower for
the outreach approach (65.8% versus 91.8%, respectively).
Only one study reported the proportion of identified
HCV-infected individuals that started treatment (37%)
[53], but did not report how many of those reached a
sustained virological response (SVR).
Nonintegrated HCV screening programs in intermediate
to high HCV-prevalence countries (n = 4)
Program characteristics
Table 1 presents the four nonintegrated HCV screening
programs that were performed in intermediate to high
HCV-prevalence countries (Taiwan [n = 2], Pakistan [n = 1]
and Egypt [n = 1]). All studies targeted the general popula-
tion; one targeted children less than 16 years of age. A
study from Egypt reported household visits to personally
invite individuals for screening [55]; the study among
children reported personal invitations (method not spe-
cified) [56]. All except the study among children re-
ported the use of media activities to attract individuals
for screening. A risk-based screening selection was used
in the program in Egypt, where screening was limited
to those with symptoms and ALT levels ≥ 2 times the
upper limit of normal. None of the studies reported the
possibility for individuals to participate anonymously.
Two studies reported about the costs for participants to
be screened; one of them offered screening free of cost,
whereas the other program [57] offered screening at
20% of the market value. None of the studies used a
comparison group for evaluation purposes. With re-
spect to screening procedures, all four studies used
venipuncture for specimen collection. A study from
Pakistan [57] used a rapid HCV antibody test. In most
(3/4) studies, participants were also screened for other
infections (mostly HBV) but not for HIV.
Program outcomes
The number of individuals screened for HCV antibodies per
program ranged from 47 to 157,720. The screening uptake
was reported in two studies; it was very low (<1%) in a city
screening program in Pakistan [57], and very high (93.6%)
in a screening program in kindergartens and schools in
Taiwan [56]. Although the screening uptake in the latter
was high, the prevalence was low (0.9%). The HCVprevalences in the other programs varied from 4.4% in a
community-based screening program in Taiwan [58] up to
78.8% in a program in Egypt that limited screening to those
with symptoms and increased ALT levels [55]. None of the
studies reported the proportion of HCV-infected patients
that started treatment and/or reached SVR.
Integrated HCV screening programs
We identified 41 HCV screening programs in the follow-
ing clinics that offer care not related to liver disease:
sexually transmittable diseases (STD) clinics (n = 11); GP
clinics (n = 10, including two programs that also used a
nonintegrated approach); Veterans Affairs (VA) clinics
(n = 5); antenatal/obstetric/fertility clinics (n = 5); clinics
for psychiatric patients (n = 3); and other clinics or ser-
vices (n = 7). Tables 2, 3, 4, 5, 6 and 7 present the pro-
grams separately for each type of setting. All programs
were carried out in low HCV-prevalence countries.
Clinics for sexually transmitted diseases (n = 11)
Program characteristics
The majority (7/11) of the HCV screening programs in
STD clinics were carried out in the USA (see Table 2).
None of the studies reported the use of personal invita-
tions or media to promote HCV screening. In five of the
11 programs, screening was limited to high-risk groups
for HCV, varying from single groups (e.g., people with a
history of IDU [64], or MSM [60]) to individuals from
multiple risk groups, such as those who have had body
piercing or tattooing in unsanitary conditions, transfu-
sion recipients before 1987, or those who have had a
needlestick injury [59]. None of the studies reported
whether or not individuals were charged for screening,
or whether anonymous participation in the screening
program was possible. None of the programs used a
comparison group for evaluation purposes. All programs
used venipuncture for specimen collection.
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 618 to 90,424. Six of the 11
programs reported the screening uptake, which varied
from 14.0% to 95.8%. The HCV prevalence varied from
0.1% to 28.0%. Of the five studies that limited HCV
screening to HCV risk groups, four reported a high
prevalence (>15%). In contrast, the prevalences in the six
studies without a risk selection varied from 0.1% to
4.9%. In all programs at the STD clinics, a history of
IDU was found in the risk profile of the identified HCV-
infected individuals, or was found associated with HCV
infection. None of the studies reported the proportion of
HCV-infected patients that started treatment and/or
reached SVR.
Table 1 Nonintegrated screening programs in intermediate to high HCV-prevalence countries (>2%)
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annually for 2 years
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anti-HCV and HCV RNA.





RNA rate: 27.3% (3/11)
Start treatment: NR
SVR: NR
Note: CI = confidence interval; NR = not reported; IDU = injecting drug use; HCV = hepatitis C virus; HBV = hepatitis B virus; HAV = hepatitis A virus; HEV = hepatitis E virus; CMV = cytomegalovirus; ALT = alanine
aminotransferase; AST = aspartate aminotransferase; SVR = sustained virological response.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below (see ***), or dried blood spots or oral fluid
samples were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).



















Table 2 Integrated screening programs at clinics for sexually transmitted diseases (STD)
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In total, 136/165 were
interviewed of whom
44% had no medical
insurance, but 87%
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776 substance abuse
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Of the antiHCV positive
individuals, 60.1%
(1719/2858) were






Note: CI = confidence interval; NR = not reported; STD = sexually transmitted disease; BBV = blood-borne virus; IDU = injecting drug use; HCV = hepatitis C virus; HBV = hepatitis B virus; HAV = hepatitis A virus;
HIV = human immunodeficiency virus; MSM =men who have sex with men; SVR = sustained virological response.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below, or dried blood spots or oral fluid samples were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).
aHistory of IDU, body piercing/tattooing in unsanitary conditions, transfusion recipients before 1987, needlestick injury, hemodialysis patients, those born to mothers with documented HCV infection, individuals who



















Table 3 Integrated screening programs at general practitioner (GP) clinics
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Note: CI = confidence interval; NR = not reported; IDU = injecting drug use; HCV = hepatitis C virus; HBV = hepatitis B virus; HIV = human immunodeficiency virus; ALT = alanine aminotransferase; AST = aspartate
aminotransferase; SVR = sustained virological response.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below, or dried blood spots or oral fluid samples were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).
aThese programs combined a nonintegrated screening approach with integrated screening at the GP clinic (see Additional file 1: Table S1). Here only results of the integrated screening are presented.
bMédecins du Monde (‘Doctors of the World’) is an international humanitarian organization providing medical care to vulnerable populations.
cTransfusion before 1991, history of drug use, history of gastroscopy, contact with HCV infected person (spouse or other family member, occupational exposure, active or former imprisonment, history of invasive



















Table 4 Integrated screening programs at VA clinics










































2 years None Yes, only those




NR Scr. uptake: NR NR In total, 520/681 were HCV RNA
positive of which 430 referred to
a specialist, of which 88.8%
(382/430) attended an
appointment. Of those, 32.5%
(124/382) received treatment






RNA rate: 76.4% (520/681)
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Of the newly diagnosed, 46.9%
(122/260) had chronic HCV, of
which 46.7% (57/122) were
treatment eligible. Of those,
31.6% (18/57) received
treatment and 33.3% (6/18)
reached an SVR.
Outcomes:
RNA rate: 46.9% (122/260)




2000-2001 Veterans USA (1.9%):
Palo Alto
VA clinic 12 months None Yes,
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NR Scr. uptake: NR NR In total, 362/536 patients were
evaluated of which 84.8% (307/
362) had chronic HCV. Of those,
18.6% (57/307) were treatment
eligible of whom 24.6% (14/57)
completed treatment with long-




























In total, 48.7% (38/78) of the
patients remained abstinent for 6
months and 30 were indicated for





















































































Note: CI = confidence interval; NR = not reported; VA = veterans affairs; IDU = injecting drug use; HCV = hepatitis C virus; CHCV = chronic hepatitis C virus; HIV = human immunodeficiency virus; LFT = liver function test;
SVR = sustained virological response; PCR = polymerase chain reaction.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).
****HCV-antibody prevalence is considered valid, but reflecting chronic HCV infection (data were collected after 1993, and reactive HCV antibody test results were confirmed by PCR).
aVietnam-era veteran, transfusion of blood of blood products before 1992, history of IDU, history of snorting cocaine, history of 5 or more drinks a day for 10 or more years in your lifetime, history of multiple (10 or
more) sexual partners in your lifetime, a man who has sex with men, history of exposure to blood on skin or mucous membranes, required chronic hemodialysis, have a tattoo or body piercing, have had a positive test
for HIV or hepatitis B, have been told that you have unexplained liver disease.
bBlood transfusion prior to 1992, IV drug use (even once), snorting of cocaine, blood exposure, sexual promiscuity (>10 lifetime sex partners), renal dialysis, tattoo or body piercing, excessive alcohol use.
cVietnam-era veteran, transfusion of blood products prior to 1992, history of IDU, blood exposure in or through skin or mucous membranes, multiple sexual partners (past or present), hemodialysis, tattoo or repeated body



















Table 5 Integrated screening programs in antenatal/obstetric/fertility clinics












































HBV, HIV No NR Scr. uptake: NR NR In total, 73.0% (84/115)
of patients had chronic
HCV, of whom 55.9%
(47/84) were lost to
follow-up, 10.7% (9/84)
deferred treatment,
4.8% (4/84) were on
treatment, and 17.9%
(15/84) completed
treatment. Of these 15,
12 achieved SRV, 1






























































In total, 96.2% (75/78)
of the patients returned

























In total, 71.1% (27/38)







































































Note: CI = confidence interval; NR = not reported; IDU = injecting drug use; HCV = hepatitis C virus; CHCV = chronic hepatitis C virus; HIV = human immunodeficiency virus; HBV = hepatitis B virus; ALT = alanine
aminotransferase; SVR = sustained virological response; PCR = polymerase chain reaction.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below, or dried blood spots or oral fluid samples
were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).



















Table 6 Integrated screening programs in psychiatric clinics






















































All patients were referred to a
specialist; after two years, none
had started treatment. One
patient became unstable
psychologically after the








RNA rate: 50.0% (4/8)


















6 months None Unit A: No;















- History of IDU
All patients were offered
post-test counseling and were








































All positive patients received
post-test counseling and were






Note: CI = confidence interval; NR = not reported; IDU = injecting drug use; HCV = hepatitis C virus; SVR = sustained virological response.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below (see ***), or dried blood spots or oral fluid
samples were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis



















Table 7 Integrated screening programs integrated in other clinics or services







































































All patients were referred for
medical follow-up. In total,
36.4% (4/11) attended, of
which 50.0% (2/4) had
chronic HCV. Liver biopsy
showed minimal activity, and
treatment was not indicated
Outcomes:
RNA rate: 50.0% (2/4)




















No NR Scr. uptake: NR NR Counseling sessions were
offered to provide education
to prevent infection
transmission, and HCV infected
couples are encouraged
to avoid marriage. No results












































Patients were referred to their
family physician (no results
reported).
Outcomes:
RNA rate: 73.3% (11/15)




















No NR Scr. uptake:
66.2% (55/82)
NR Subsequent attendance at STI
services remained low.
Follow-up of the HCV-



























Table 7 Integrated screening programs integrated in other clinics or services (Continued)
Cohen, DE,
2006 [96]


































Patients were referred to their



















































possibility of undergoing a
follow-up for the clinical and
laboratory evaluation of he-
patic involvement (no results
reported).
Outcomes:















No NR Scr. uptake:
71.1% (529/
744)
NR All patients who tested










Note: CI = confidence interval; NR = not reported; IDU = injecting drug use; HCV = hepatitis C virus; CHCV = chronic hepatitis C virus; HBV = hepatitis B virus; HAV = hepatitis A virus; HDV = hepatitis delta virus;
HIV = human immunodeficiency virus; ALT = alanine aminotransferase; MSM =men who have sex with men; SVR = sustained virological response; PCR = polymerase chain reaction.
*HCV-antibody prevalence is considered suboptimal (data were collected before 1994 when sensitivity/specificity of tests was not optimal, or reactive HCV-antibody test results were not confirmed by immunoblot).
**The reliability of the reported HCV-antibody prevalence is undecided (data were collected after 1993, but the diagnostic tests are unspecified, or other than described below, or dried blood spots or oral fluid samples were used).
***HCV-antibody prevalence is considered valid; data were collected after 1993, and reactive HCV-antibody test results were confirmed by second or higher generation immunoblot assays from Ortho, Chiron, Novartis
(RIBA), Innogenetics (LiaTek), Pasteur (DECISCAN HCV), Genelabs Diagnostics (HCV BLOT), or Mikrogen (recomBlot HCV IgG 2.0).
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Program characteristics
The majority (8/12) of the HCV-screening programs in
GP clinics were carried out in France (see Table 3). In
most programs (9/12), screening was limited to HCV risk
groups within the GP-patient population (specific migrant
groups [46,47]; risk groups such as those with a history of
IDU and recipients of blood transfusions before 1991
[70,72,73,75-78]). One program was carried out in a
health care center that attracted people with poor access
to health care, mostly migrants [44], and one was carried
out in an area of low socioeconomic status [71]. In two of
the 12 programs, individuals who were in the GP’s waiting
room were approached and invited for screening [44,46],
and five programs used media activities to attract individ-
uals for screening. Of the 12 studies, four reported that
screening was free of cost [70,73,78,99], whereas the
others did not report participants’ costs for screening.
Only the screening program among people with poor
access to health care offered the possibility of anonymous
screening [44].
In reference to screening procedures, all but two studies
used venipuncture for specimen collection. Two screening
programs used oral fluid HCV antibody tests, followed by
blood tests for those who tested positive. The majority
(9/12) of the programs focused solely on HCV screen-
ing. The three programs that screened predominantly
migrants also included HBV screening [44,46,47].
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 117 to 15,952. Six of the 12 pro-
grams reported the screening uptake, which varied from
27.8% to 82.5%. The HCV prevalence varied from 0% to
30.8%. Of the 12 programs, three primarily screened mi-
grants (prevalences 0%, 1.2% and 5.8%), seven used risk
factors other than being a migrant as criteria for screening
(prevalences 1.4% to 30.8%), and one was performed in an
area of low socioeconomic status (prevalence 12.8%). In
contrast, one program that did not use risk factors as
screening criteria, and was not performed in an area of
low socioeconomic status, found a relatively low preva-
lence of 0.4% [74]. We did not notice clear differences in
screening uptake or HCV prevalence related to the use of
media to attract individuals for screening. Further, we
could not assess whether personally inviting individuals
for screening or screening for more than just HCV could
have influenced the screening uptake, since these studies
did not report the screening uptake.
Four studies checked the results of their screening pro-
gram against data collected in the same period in compari-
son clinics or data collected prior to the screening
program. A study from the Netherlands concluded that the
addition of primary care practice support leads toconsiderable improvements in medical awareness regarding
HCV infection in primary care, which is likely to have a
positive effect on case finding (that effect, however, could
not be indisputably demonstrated) [76]. A study from France
concluded that information and training that is adapted to
GPs’ medical practice can lead to more active involvement
of GPs in screening for HCV infection [77]. During the
intervention the number of GPs that prescribed HCV
screening increased, and more HCV-infected patients
were detected compared with the year before. Another
study from France compared two interventions in the GP
clinic; GPs in intervention 1 prescribed HCV screening if
HCV risk factors were identified during questioning of pa-
tients, whereas GPs in intervention 2 placed posters and
leaflets on HCV risk factors in their waiting rooms to mo-
tivate patients at risk to discuss screening [78]. The num-
bers of tests prescribed by GPs was relatively low in
both interventions, and outcomes of the two interven-
tions with regard to the number of tests and the HCV
prevalence were comparable. In a study from Scotland,
HCV screening was offered to all GP visitors aged 30–
54 years and 117 individuals were screened (prevalence:
12.8%, 15/117), whereas in a comparison clinic, where no
intervention for HCV screening was introduced, no indi-
viduals were screened for HCV [71]. Two of these pro-
grams reported the proportion who started treatment (18%
and 38%), but only one of these two programs reported the
proportion of treated individuals (n = 2) who reached SVR
(50%, n = 1) [71].
Veterans affairs clinics (n = 5)
Program characteristics
Table 4 presents the five HCV screening programs in VA
clinics in the USA. No personal invitations or media ac-
tivities were reported. All screening programs limited
the screening to risk groups within the veteran popula-
tion. In one program, screening was limited to veterans
who were admitted for an alcohol and noninjecting drug
rehabilitation program [82], while other programs used
an extensive list of risk factors, including history of drug
use, blood transfusion prior to 1992, and Vietnam vet-
eran. None of the programs reported whether or not in-
dividuals could participate anonymously, participants’
costs for screening, or a comparison group for evaluation
purposes. All programs used venipuncture for specimen
collection and screened solely for HCV.
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 338 to 12,485. The screening
uptake was described in three of the five programs, vary-
ing from 41.9% to 99.4%. The HCV prevalence in most
programs was around 5%, but the program among vet-
erans who were admitted to an alcohol and noninjecting
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(23.1%). The proportion of patients that started treat-
ment was described in three studies and varied from
15% to 38%. Four studies reported the SVR rate among
those who started treatment, ranging from 33% to 47%.
Antenatal/obstetric/fertility clinics (n = 5)
Program characteristics
Of the five programs, three were carried out in the UK,
one in the USA and one in Brazil (see Table 5). The pro-
grams targeted pregnant women, except for a British
study in a fertility clinic that was targeted at couples.
Media activities to promote the screening programs
were described in only one of the five studies; this study
used information leaflets to inform women about the
screening program, and a personal invitation for partici-
pation by the midwife [87]. None of the programs used a
risk assessment strategy to limit screening to those at
risk. The programs did not report the possibility to
screen anonymously, or a comparison group for evalu-
ation purposes. The one program reporting screening
costs was free of cost to participants [88].
With respect to screening procedures, all but one
study used venipuncture for specimen collection. One
study used DBS for anti-HCV screening and a second
generation ELISA followed by HCV RNA testing using
venous blood for confirmation [88]. In all but one pro-
gram, participants were also screened for other infec-
tions (mainly HIV and HBV) or elevated liver enzymes
(ALT/AST).
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 1,658 to 31,081. In the two
studies reporting screening uptake, rates were very high
(≥98%). In all but one program, the HCV prevalences
were low, varying from 0.2% to 0.8%. In women at risk
for perinatal complications, HCV prevalence was 4.6%
[86]. In one of the five programs, results of the clinical
follow-up and treatment were reported, showing that
67.9% of those identified with chronic HCV started
treatment after delivery, and 80% of those who com-
pleted treatment achieved SVR [84].
Psychiatric clinics (n = 3)
Program characteristics
Of the three HCV screening programs in psychiatric
clinics, two were carried out in Australia, and one in the
USA (see Table 6). One program aimed to evaluate
whether screening by risk factors would be effective, and
limited the HCV screening program in one unit to those
with a history of IDU and those exposed to contami-
nated blood products, whereas in the other unit all pa-
tients were screened [90]. In the other two programs, norisk selection was used for participation in the screening
program. One program promoted screening by using
media [91]. The programs did not offer the possibility to
screen anonymously, and did not report about participants’
costs for screening. Concerning screening procedures, all
studies used venipuncture for specimen collection, and all
studies exclusively screened for HCV.
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 36 to 98. All programs re-
ported the screening uptake, varying from 20.5% to
100%. The HCV prevalences varied from 3.2% in the
unit without pre-screening risk selection [90], to 41.7%
in the unit where screening was limited to those who re-
ported a history of IDU or exposure to contaminated
blood products. Noninjecting drug use and history of
IDU were reported as the main risk factors among the
identified cases. All three programs referred the HCV-
infected individuals to a specialist. Of interest, in two
programs [90,91], post-test counseling addressing vari-
ous topics (e.g., education about the illness, risk behav-
ior, safe injection practices, secondary prevention) was
also offered to those who reported risk factors but tested
HCV negative.
One of the three studies reported that their program
was based on psychosocial theory or knowledge about
determinants facilitating participation in HCV screening
programs. This program promoted screening by using
leaflets outlining HCV, its risk factors, and the import-
ance of screening, and used individually tailored pre-
and post-test counseling that was adapted to individual
knowledge and cultural understandings where appropri-
ate [91]. Although the uptake of screening in that study
was relatively low (20.5%), the prevalence was relatively
high (19.7%), especially considering the fact that no pre-
screening risk selection was used.
Other clinics (n = 7)
Program characteristics
In total, seven HCV screening programs were integrated
in other clinics or services (see Table 7). These programs
varied widely, from screening patients at an emergency
health unit in France [92] to screening couples that wish
to get married in Saudi Arabia [93]. Two programs tar-
geted MSM; one in an outreach service for HIV point-
of-care testing in the UK [95], and another in a commu-
nity care facility in the USA [96].
The study in the USA reported the use of media activ-
ities to attract participants, wherein MSM were recruited
through advertisements as well as by referral of medical
staff [96]. Two of the seven studies used a prescreening
selection; a program at an emergency health unit only
screened those with a reported risk factor [92], and in
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during routine medical check-up were screened for HCV
[94]. None of the programs reported about the possibility
of anonymous screening, or a comparison group for evalu-
ation purposes. The one study reporting about participants’
costs for screening mentioned that it was free [96]. With re-
spect to screening procedures, all studies used venipuncture
for specimen collection. Four of the seven programs also
screened for other diseases (mainly HBV).
Program outcomes
The number of individuals screened for HCV antibodies
per program ranged from 55 to 74,662. The screening
uptake was reported in three out of seven programs,
varying from 66.2% to 77.6%. The HCV prevalence var-
ied from 0.3% in a mandatory premarital screening
program in Saudi Arabia [93] to 11.5% in a program for
MSM [96]. Only one study reported the number of
patients that started treatment, which was zero [92].
Discussion
This systematic review describes characteristics and
outcomes of HCV screening programs in the general
population, and includes 67 programs. In total, 24 of
them were exclusively set up for the purpose of HCV
screening, whereas 41 were integrated in already exist-
ing health care facilities (not aimed at HCV risk
groups), and two programs used both an integrated and
nonintegrated approach. Altogether, the programs that
were published identified approximately 25,700 HCV-
infected individuals. Clearly, large-scale, and long-term
screening and referral programs are needed to address
the HCV-related burden of disease in an era of potent
therapy for HCV.
The programs were highly heterogenic in their
organization, recruitment, and screening procedure, and
the vast majority did not use a comparison group to as-
sess the effectiveness of their screening program. Hence,
we cannot draw firm conclusions as to which screening
program strategy, or which program characteristic (e.g.,
free-of-cost vs. low-cost screening, anonymous vs. nona-
nonymous screening, use of particular media to promote
screening) is more effective than another in attracting or
motivating individuals for screening or in attracting those
at higher risk for HCV. Screening programs that compare
different recruitment and screening strategies are needed
to gain insight into effectiveness of strategies and program
characteristics.
In addition, many studies did not report program
characteristics (e.g., the laboratory tests that were used).
The same was true for screening uptake and follow-up data
regarding HCV-related care, and even if reported, there
was not much consistency (e.g., some reported the SVR
rate among those who completed treatment, whereasothers reported that treatment was ‘rather successful’). The
underreporting and the lack of uniformity of data report-
ing greatly hinder the comparison of screening programs.
Data reporting standards (see Parameters of screening
programs) are needed to be able to compare screening
program characteristics and outcomes in order to find
out which factors are effective. If demonstration projects
for HCV screening are not able to demonstrate direct ef-
fects in terms of number of individuals who tested posi-
tive for HCV that are linked to care, secondary evaluation
measures could be used. For instance by monitoring rates
of HCV screening and positivity in the hospital or referral
laboratory and by comparing these data with data from
previous years or from hospitals or laboratories that were
not involved in the demonstration project.
In general, we noticed relatively high HCV prevalences
in programs that used a prescreening selection based on
HCV risk factors (especially in programs that used ele-
vated ALT or a history of IDU as indications for HCV
screening) or migrant status, in programs that were car-
ried out in intermediate to high HCV-prevalence coun-
tries or regions, and in programs in psychiatric clinics.
Also, relatively high HCV prevalences were found in
nonintegrated programs in low HCV-prevalence coun-
tries that targeted the general population (see Additional
file 1: Table S1, row 1–7), even without a prescreening
risk assessment. These programs might have screened a
self-referred population, and may have attracted those at
risk of HCV in the general population, and therefore ob-
served prevalences are higher than those in the general
population. For the study by Hayashi etal (see Additional
file 1: Table S1), screening was performed in a specific
region in Japan with a presumably high HCV prevalence,
explaining the very high prevalence that was found. In
most studies, a history of IDU was the main risk factor
among the identified HCV-infected individuals. In gen-
eral, low HCV prevalences were found in programs that
targeted health care workers, and in programs that were
carried out in antenatal clinics. Programs in STD and
GP clinics that did not use a prescreening risk selection
also found relatively low HCV prevalences.
Only one study reported that the promotion of the
screening program was based on theoretical insights or
knowledge about determinants facilitating participation
in screening programs. None of the studies reported the
use of simple tools that may increase the screening up-
take, such as reminder messages [100], or support with
planning of when and how to get screened (i.e., creating
implementation intentions [101]). In many studies, and
especially those describing nonintegrated programs, the
uptake of screening was not reported.
We found that integrated screening programs in general
screened a larger number of individuals than did noninte-
grated screening programs in low HCV-prevalence
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tages in that they do not have to attract their target popula-
tion for screening, and they can use a facility that is
familiar to the public. In addition, they can facilitate con-
tinuous screening and follow-up of individuals at relatively
low cost, whereas nonintegrated programs offer screening
usually for a limited period. On the other hand, integrated
screening programs only reach those who have a reason to
visit such facilities (unless media campaigns have been
used to attract more people), whereas nonintegrated pro-
grams may attract a different risk population that otherwise
would not be screened and do not perceive themselves at
risk for HCV (i.e., the hidden population). We believe that
both approaches are useful and complementary. In
addition, since nonintegrated screening in general is more
complex to organize, it may be efficient to screen for other
diseases simultaneously, when risk groups overlap.
We identified several studies that did not confirm HCV
antibody test results. Many of the identified programs tar-
geted asymptomatic individuals in the general population
with a relatively low HCV prevalence. In such populations,
unconfirmed HCV antibody test results may include 35%
(range: 15%–60%) false-positive test results [102]. Hence,
the program outcomes that are reported may include a
substantial degree of uncertainty, and should be inter-
preted with care. We like to emphasize that HCV screening
programs should use validated screening methods, and de-
scribe the tests that were used when publishing the results
of their screening programs.
As for study limitations, the majority of the screening
programs that were evaluated in this review occurred in
just a few countries (USA, UK, and France), most likely
since this review was limited to studies published in
English, French, German, Spanish, and Dutch. Therefore,
the results may not be generalizable to other (non-West-
ern) countries or countries with a higher HCV preva-
lence. With respect to publication bias, this review only
includes screening programs that were published and
programs that were successful in identifying HCV-
infected individuals may have been more likely to be
published. However, we did identify several programs in
which no individuals were diagnosed. Furthermore, as
identification of HCV-infected individuals serves a clinical
goal and not necessarily a scientific goal, not all screening
efforts have been evaluated or published. Our search iden-
tified several announcements of HCV screening activities
[103,104] or cost-effectiveness evaluations of screening ac-
tivities [105] that did not provide any further information
about the screening program and/or outcomes. Further,
our review describes several screening programs, but it
cannot determine the efficiency and effectiveness of these
screening programs in preventing future HCV-related
morbidity and mortality. Measuring these effects of HCV
screening programs is a challenge because randomized,controlled trials or comparison groups and decades of
follow-up time are required. As an alternative method,
mathematical modelling studies can be useful to estimate
long-term effects of screening programs (e.g., [106,107]),
especially when certain program outcomes (e.g., participa-
tion rate, prevalence) are used as parameters in the model.
The efficiency and effectiveness of screening also depends
on the uptake and outcomes of therapy and other prevent-
ive measures that may follow from diagnosis. Efficiency
relates to the number needed to be screened to identify a
treatable case of HCV. Surprisingly, most studies did not
report such data, and merely mentioned that HCV-
infected individuals were notified of their test result and
referred for clinical care. Following Wilson and Jungners
third screening principle [108], facilities for diagnosis and
treatment should be available. This means that the screen-
ing program itself is as important as the efforts that are
undertaken to bring identified patients into care and have
them benefit from preventive measures and/or treatment.
Hence, evaluation reports of screening programs should in-
clude clinical follow-up and systematically report outcomes.
A recent systematic review by Jones etal on the effect-
iveness and cost-effectiveness of interventions aimed at
raising awareness of and/or increasing engagement in case
finding and screening with high-risk groups for HCV and
HBV and practitioners included only programs with a
comparison group (e.g., randomized controlled trials, pre-
and postintervention data, repeated cross-sectional stud-
ies) [109]. About half of the studies (12/25) included in
that review were aimed at high-risk groups for HCV that
are relatively easy to target, such as current IDU and
incarcerated individuals, whereas our review includes
studies that aimed to identify the hidden population of
HCV-infected individuals. Jones etal identified drug ser-
vices and primary care as settings in which interventions
could effectively increase screening uptake. They also
found that DBS screening in addition to venipuncture
might increase HCV screening uptake in drugs services or
prisons. In our review, a few studies reported the use of
home collection tests, DBS, or oral fluid tests, but these
studies did not demonstrate high screening uptake. Fur-
ther insight into the effect of alternative noninvasive
screening procedures on screening uptake is needed. As in
our review, Jones etal concluded that improvement of
health outcomes following diagnosis for those identified
with chronic HCV deserves careful attention.
In the United States it has recently been recom-
mended that all people born between 1945 and 1965
should be offered a one-time screening without prior
risk assessment [110], since HCV prevalence in this
group is four times greater than adults aged 20 years or
older who were born outside of the birth cohort, and
identifying this group through a high risk profile has
been unsuccessful so far. More importantly, this
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assuming an uptake of 15% [106]. Although a relatively
low uptake of 15% was assumed in the cost-effectiveness
model in the USA, those who participate may not be
representative for the total population of baby boomers.
It may be that those at lower risk for HCV (i.e., the
worried-well) could be more likely to respond. Thus,
although it may be promising, the effectiveness of such
an intervention needs to be demonstrated in practice.
Nevertheless, it should be examined whether it is feas-
ible and cost-effective to implement such a birth cohort
screening in countries with a lower HCV prevalence.Conclusions
HCV infection has serious health implications and, at
the start of the era of potent therapy for HCV, screening
programs are not yet reaching all potentially infected in-
dividuals worldwide. Therefore more effective programs
are urgently needed. This review identified 67 screening
programs that targeted HCV risk groups that are hidden
in the general population. Relatively high HCV preva-
lences were found in programs that used a prescreening
selection based on a HCV risk profile or migrant status,
in programs that were carried out in intermediate to
high HCV-prevalence countries or regions, and in pro-
grams in psychiatric clinics. In general, low HCV preva-
lences were found in programs that targeted health care
workers and pregnant women. The reported use of mo-
tivational communication based on theory and/or deter-
minants facilitating screening, and tools to increase
HCV screening uptake were virtually absent. Compari-
son of the screening programs was strongly hindered by
the lack of reported data on screening uptake, program
characteristics, the type of diagnostic tests used, and
clinical outcomes. In addition, only a few programs used
a comparison group to evaluate program effectiveness.
We suggest that for low HCV-prevalence populations,
the use of prescreening selection criteria should be con-
sidered to increase efficiency. In addition, to be able to
assess screening program effectiveness, programs using a
comparison group are needed. To improve comparability
of screening programs and outcomes, it is necessary for
all programs to systematically report program character-
istics, screening uptake, the type of diagnostic tests that
were used, as well as clinical outcomes.Additional file
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